RPG Life Sciences share news, announcements and annual reports
NSE: RPGLIFEBSE: 532983Pharmaceuticals & BiotechnologySmall Cap
RPG Life Sciences Limited · Face value ₹8 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 2008
Last close ₹2,844.00up ₹7.90 (0.28%)BSE ₹2,847.20
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,836.10.
28 Oct: open ₹2,854.00, high ₹2,862.60, low ₹2,800.00
52-week range of traded prices to 28 Oct 2026
₹1,733.00Low, 23 Mar 2026₹3,127.80High, 25 Sep 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,704 Cr923rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.38
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 7.77
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 21.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,99740.5% delivered
RPG Life Sciences disputes and clarifications
15 filed, newest first.
Sep 2026
23 Sep · Legal
The exchange asked on 23 Sep 2026
Jun 2026
12 Jun · Legal
The exchange asked on 11 Jun 2026
Feb 2026
3 Feb · Legal
Exchange has sought clarification from RPG Life Sciences Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act. -2. 2013 or as per Indian Accounting Standard. The response of the Company is awaited.
Oct 2025
21 Oct · Legal
The exchange asked on 21 Oct 2025
Mar 2024
Feb 2024
23 Feb · Legal
Exchange has sought clarification from RPG Life Sciences Limited with respect to announcement dated 22-Jan-2024, regarding disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 13, 2023. On basis of above the Company is required to clarify following: 1. Disclosure of communication received from any regulatory, statutory, enforcement or judicial authority as per Regulation 30(13) of SEBI (LODR) Regulations 2015. The response of the Company is awaited.
Apr 2021
21 Apr · Legal
The exchange asked on 20 Apr 2021
Jan 2021
21 Jan · Legal
The exchange asked on 20 Jan 2021
May 2018
8 May · Legal
Exchange has sought clarification from RPG Life Sciences Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.
Mar 2017
29 Mar · Legal
The exchange asked on 27 Mar 2017
Jan 2017
6 Jan · Legal
The exchange asked on 5 Jan 2017
Jul 2016
27 Jul · Legal
Exchange has sought clarification from RPG Life Sciences Limited with respect to announcement dated 27-Jul-2016, regarding (a) appointment of Mr. Yugal Sikri as an Additional Director of the Company. (b) Resignation of Mr. Sachin Raole- CFO & Sr. VP Corporate Services and appointment of Mr. Mahesh Narayanaswamy as Vice President Finance of the Company with effect from July 1, 2016. On basis of above you are required to clarify following -1. Reason for change viz. appointment, resignation, removal, death or otherwise;2. Date of appointment/cessation (as applicable) & term of appointment;3. Brief profile (in case of appointment);4. Disclosure of relationships between directors (in case of appointment of a director).The response of the Company is awaited.